Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

docetaxel

  • Open Access
    Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
    YUTARO KUBOTA, QINGHONG HAN, NORIYUKI MASAKI, CHIHIRO HOZUMI, KAZUYUKI HAMADA, YUSUKE AOKI, KOYA OBARA, TAKUYA TSUNODA and ROBERT M. HOFFMAN
    Anticancer Research December 2022, 42 (12) 5819-5823; DOI: https://doi.org/10.21873/anticanres.16089
  • You have access
    β-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines
    MASAKO MUGURUMA, MARIKO ASAOKA, SAEKO TERAOKA, KANA MIYAHARA, TAKAHIKO KAWATE and TAKASHI ISHIKAWA
    Anticancer Research October 2022, 42 (10) 4735-4742; DOI: https://doi.org/10.21873/anticanres.15978
  • You have access
    Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study
    JIAN-RI LI, SHIAN-SHIANG WANG, CHUAN-SHU CHEN, CHENG-KUANG YANG, KEVIN LU, CHEN-LI CHENG, SHENG-CHUN HUNG, SHU-YEN CHEN, CHIANN YI HSU and KUN-YUAN CHIU
    Anticancer Research October 2022, 42 (10) 4857-4866; DOI: https://doi.org/10.21873/anticanres.15991
  • You have access
    Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma
    KEN SASAKI, YUSUKE TSURUDA, MASATAKA SHIMONOSONO, MASAHIRO NODA, YASUTO UCHIKADO, TAKAAKI ARIGAMI, DAISUKE MATSUSHITA, SHINICHIRO MORI, AKIHIRO NAKAJO, HIROSHI KURAHARA and TAKAO OHTSUKA
    Anticancer Research August 2022, 42 (8) 3905-3911; DOI: https://doi.org/10.21873/anticanres.15884
  • You have access
    Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy
    MOTOHIRO FUJIWARA, RYO FUJIWARA, TOMOHIKO OGUCHI, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, JUNJI YONESE and TAKESHI YUASA
    Anticancer Research April 2022, 42 (4) 2123-2130; DOI: https://doi.org/10.21873/anticanres.15694
  • Open Access
    Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice
    ATSUSHI MIZOKAMI, KOSHIRO NISHIMOTO, HIDEYASU MATSUYAMA, TOMOHIKO ICHIKAWA, SATORU TAKAHASHI, HIROAKI SHIINA, KATSUYOSHI HASHINE, YUTAKA SUGIYAMA, MANABU KAMIYAMA, HIDEKI ENOKIDA and KENICHI NAKAJIMA
    Anticancer Research March 2022, 42 (3) 1465-1475; DOI: https://doi.org/10.21873/anticanres.15617
  • You have access
    Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study
    MIIKKA LEHTONEN, JORMA SORMUNEN, MARIE HJÄLM-ERIKSSON, CAMILLA THELLENBERG-KARLSSON, TEPPO HUTTUNEN, CLAES GINMAN, PIRKKO-LIISA KELLOKUMPU-LEHTINEN and On Behalf of the Investigators of the Scandinavian Prostate Cancer Group Study No 13
    Anticancer Research January 2022, 42 (1) 87-92; DOI: https://doi.org/10.21873/anticanres.15460
  • You have access
    Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis
    KANAKO MAMISHIN, YOICHI NAITO, SHOGO NOMURA, GAKUTO OGAWA, KUMI NIGUMA, KAEDE BABA, SAEKO SAKAEDA, HIROMICHI NAKAJIMA, SHOTA KUSUHARA, CHIKAKO FUNASAKA, TAKEHIRO NAKAO, YOKO FUKASAWA, CHIHIRO KONDOH, KENICHI HARANO, TAKAHIRO KOGAWA, NOBUAKI MATSUBARA, AKO HOSONO, TOSHIKATSU KAWASAKI and TORU MUKOHARA
    Anticancer Research December 2021, 41 (12) 6217-6224; DOI: https://doi.org/10.21873/anticanres.15441
  • You have access
    Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations
    KYOUNG-HWA SON, MIN-YOUNG KIM, JUNG-YOUNG SHIN, JEONG-OH KIM and JIN-HYOUNG KANG
    Anticancer Research October 2021, 41 (10) 4807-4820; DOI: https://doi.org/10.21873/anticanres.15296
  • You have access
    Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells
    HIROMITSU WATANABE, ASUKA KAWAKAMI, RYO SATO, KYOHEI WATANABE, YUTO MATSUSHITA and HIDEAKI MIYAKE
    Anticancer Research August 2021, 41 (8) 3753-3758; DOI: https://doi.org/10.21873/anticanres.15167

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire